Fresenius SE reports first-quarter earnings miss

8 articles · Updated · Bloomberg · May 6

The German healthcare group posted €678 million in first-quarter EBIT, up 6% at constant currency but below the €686 million analyst consensus.
Fresenius said pricing pressure in China weighed on its clinical nutrition business, contributing to the narrower-than-expected shortfall.
The results highlight continuing challenges in China for healthcare companies, even as Fresenius still delivered year-on-year earnings growth.

With China's price-cutting policy expanding, how can foreign medical firms pivot from survival to growth?

As China squeezes foreign profits, are its own biotech champions poised for global market dominance?

Is China's VBP model a blueprint for affordable healthcare or a threat to global drug innovation?